Insightec

MR-guided Focused Ultrasound Systems

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in March 1999 by Kobi Vortman, Insightec operates with 201–500 employees. The company has raised $592.9M across 9 funding rounds from 18 investors. In June 2024, Insightec secured financing, with Fidelity Management & Research Company and Nexus NeuroTech Ventures participating.

Business overview

Insightec is a global healthcare company that leverages the therapeutic power of acoustic energy through its MR-guided focused ultrasound systems. Its Exablate Neuro platform uses sound waves, safely guided by MRI, to treat patients with medication-refractory Essential Tremor and Parkinson's Disease. The company is continuously expanding its applications into areas such as functional neurosurgery, oncology, and gynecology, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In September 2024, Insightec announced a strategic collaboration with Charles River Laboratories to advance therapeutic development using focused ultrasound in neuroscience. This partnership signals a significant validation of Insightec's core technology and its potential to accelerate innovation in neurological treatments, indicating strong forward momentum in expanding its therapeutic applications and market reach.

Company Intelligence Q&A

What was a significant recent strategic partnership for Insightec?
In September 2024, Insightec announced a strategic collaboration with Charles River Laboratories International to advance therapeutic development utilizing focused ultrasound in neuroscience.
Has Insightec recently expanded its leadership team?
In September 2024, Insightec appointed Jake Ghannam as its Chief Commercial Officer, aiming to transform patient care through focused ultrasound technology.
What was a key regulatory approval for Insightec in the past year?
In September 2023, Insightec received CE Mark approval to treat essential tremor patients' second side, expanding treatment options for individuals living with essential tremor.
What is the latest funding activity for Insightec?
In June 2024, Insightec announced financing to fund continued growth, with Fidelity Management & Research Company and Nexus NeuroTech Ventures participating.
What was a notable development regarding reimbursement for Insightec's treatments?
In March 2026, Insightec announced national reimbursement in France for MR-guided focused ultrasound to treat essential tremor.

External links